Valuation: ARRD RESE

Market Cap 9.39B 8.19B 7.73B 7.02B 13.15B 901B 13.21B 92.62B 35.74B 458B 35.28B 34.49B 1,474B P/E 2026 *
-18.3x
P/E 2027 * -14.4x
Enterprise Value 8.56B 7.46B 7.05B 6.4B 11.99B 821B 12.04B 84.41B 32.57B 418B 32.15B 31.44B 1,343B EV / Sales 2026 *
18.6x
EV / Sales 2027 * 25.6x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
17/09 Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-16-2026 09:00 AM
16/09 Arrowhead Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM
15/09 Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for Aro-Dimer-Pa Phase 1/2A Clinical Trial CI
11/09 Arrowhead Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
08/09 Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target MT
01/09 Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says MT
31/08 Arrowhead Pharmaceuticals, Inc. - Special Call
31/08 Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia MT
31/08 Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 And SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events In Patients With Severe Hypertriglyceridemia CI
24/08 Arrowhead Pharmaceuticals Presents New Clinical Data and Product Updates At European Society of Cardiology Congress CI
21/08 Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,012,680, According to a Recent SEC Filing MT
18/08 Arrowhead Pharmaceuticals' Redemplo Now Available in Germany for FCS Patients MT
17/08 Arrowhead Pharmaceuticals Lists REDEMPLO In Lauer-Taxe Database As Adjunct To Diet To Reduce Triglyceride Levels In Adult Patients With Familial Chylomicronaemia Syndrome In Germany CI
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2007
Director of Finance/CFO - 13/05/2025
Chief Tech/Sci/R&D Officer - 01/08/2022
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 19/08/2010
Director/Board Member 66 19/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
+2.12%-5.86%+161.58%+329.34% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -0.21%+1.74%+36.57%+208.32% 30.54B
Weighted average by Cap. -0.28%+1.49%+35.68%+148.22%

Financials

2026 *2027 *
Net sales 461M 402M 380M 345M 646M 44.25B 649M 4.55B 1.76B 22.5B 1.73B 1.69B 72.39B 340M 296M 280M 254M 476M 32.62B 478M 3.35B 1.29B 16.58B 1.28B 1.25B 53.36B
Net income -518M -452M -427M -388M -726M -49.75B -729M -5.11B -1.97B -25.29B -1.95B -1.9B -81.39B -650M -566M -535M -486M -910M -62.32B -914M -6.41B -2.47B -31.69B -2.44B -2.39B -102B
Net Debt -832M -726M -685M -622M -1.17B -79.87B -1.17B -8.21B -3.17B -40.61B -3.13B -3.06B -131B -683M -595M -562M -511M -956M -65.52B -960M -6.73B -2.6B -33.31B -2.56B -2.51B -107B
Logo ARRD RESE
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!